Tracking the Risk for Alzheimer’s Disease using the APT Webstudy
The Alzheimer Prevention Trials (APT) Webstudy is designed to accelerate enrollment into Alzheimer’s clinical trials by identifying and tracking individuals online, who may be at higher risk for developing Alzheimer’s. The Alzheimer’s Association estimates that 5.5 million Americans age 65 and older are currently living with Alzheimer’s dementia. It’s believed these numbers will increase by almost 30% to over 7 million people by 2025, where it’s the only top 10 cause of death that cannot be prevented, cured, or even slowed. The APT Webstudy is open to anyone over the age of 50. The goal of the APT Webstudy is to develop an online group of individuals who will allow their memory and thinking test scores to be tracked over time. Participants will have the opportunity to take online tests to assess their memory and thinking skills, gain access to their scores, and be notified of opportunities for in-person assessments and clinical trials aimed at preventing dementia. These in-person visits will be offered through the closest clinical site to participants.
Join today! New study at USC tests effectiveness of newly approved drug to help people with eczema, called Atopic Dermatitis
Atopic Dermatitis is a form of eczema that causes dry, scaly, itchy skin. More than 3 million cases are reported in the U.S. each year. People with this skin condition often have problems with bacterial skin infections caused by a specific bacteria known as, Staph aureus, or just Staph. Patients with chronic eczema often use long-term topical or oral treatments to help control their symptoms. But using these medications over long periods of time can have side effects on the body. The purpose of this study is to test the effectiveness of the drug dupilumab (dupixent), which was recently approved by the Food and Drug Administration (FDA) to offer relief to patients who cannot control their eczema with commonly used topical medications.We want to find out how dupilumab affects the amount of bacteria on the skin and the immune system of the patients, and whether it might cause less side effects. Join us today if you are between 18-65 years old with chronic eczema (Atopic Dermatitis).
A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
Seasonal influenza is responsible for approximately 226,000 excess hospitalizations annually
and despite effective antivirals causes significant morbidity and mortality (estimated
24,000-50,000 deaths each year in the United States alone). The influenza virus that emerged
in 2009 (A/California/07/2009 H1N1) caused fewer deaths (12,000 flu-related deaths in the
U.S) but in contrast to seasonal flu, nearly 90 percent of the deaths with the 2009 H1N1
occurred among people younger than 65 years of age. The CDC has defined an at-risk
population that is responsible for the majority of hospitalization and morbidity associated
with influenza. This study will evaluate the use of combination antivirals as compared to
oseltamivir alone in the treatment of influenza in an at-risk population.
Subjects who meet the CDC definition for being at-risk and that present with an
influenza-like illness will be screened for the study. Those subjects with a confirmatory
test for influenza (rapid antigen or PCR) will be randomized in a 1:1 manner to receive a
blinded study treatment consisting of either the combination of amantadine, oseltamivir, and
ribavirin or oseltamivir alone for 5 days. Clinical, virologic, and laboratory assessments
on Days 1, 3, 7, 14, and 28 will be used for both safety and efficacy analysis.
Objectives:
- To evaluate the effectiveness of combined treatment with oseltamivir, amantadine, and
ribavirin compared with oseltamivir alone for at-risk individuals with confirmed influenza
infection.
Eligibility:
- Individuals at least 18 years of age who have one or more medical conditions that may
cause complications from influenza, and have developed an influenza-like illness.
Design:
- Participants will be screened with a physical examination and medical history, along
with blood tests and throat swabs to confirm influenza infection.
- Eligible participants will be randomly assigned to take either oseltamivir alone (the
current standard treatment for influenza) or to take oseltamivir, amantadine, and
ribavirin. Participants will have additional blood samples and throat swabs taken at
the start of the study, and will be shown how to complete a study diary at home.
- Participants will receive a study medication kit containing the medication to take at
home twice a day for 5 days.
- Participants will return, with the medication kit, to the clinic on days 1 (the first
day after the start of the study), 3, 7, 14, and 28. The first visit may take 2 to 3
hours, but each subsequent visit should take approximately 1 to 2 hours. Additional
blood samples and throat swabs will be taken at these visits.
0C-14-7: A Phase 1/2A, Multicenter, Open-Label Study of Oral RxDx-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for TRKA, TRKB, TRKC, ROS1, or ALK Molecular Alterations
RXDX-101-01 is a multicenter, open-label, Phase 1/2a study in which the safety and efficacy of RXDX-101 will be evaluated in adult patients with any locally advanced or metastatic solid tumor.
The primary objective of the Phase 2a expansion cohorts is Objective Response (OR) defined as Complete Response(CR) and Partial Response (PR) at the recommended phase 2 dose of RXDX-101.
RXDX-101 is an orally available inhibitor of the tyrosine kinases TrkA, TrkB, TrkC, ROS1, and ALK. Molecular alterations to these targets are present in several different tumor types, including non-small cell lung cancer, colorectal cancer, papillary thyroid cancer, pancreatic cancer, and neuroblastoma.
The Phase 2a segment of this study will consist of 5 cohorts as described below:
Cohort #1: Participants that express TrkA. Cohort #2: Participants that express TrkB. Cohort #3: Participants that express TrkC. Cohort #4a: Participants that express ALK with an associated molecular alteration who are nave to prior treatment with ALK inhibitors. Cohort #4b: Participants that express ALK with an associated molecular alteration who have received prior treatment with one or more ALK inhibitors. Cohort #5: Participants that express ROS1
USC will only participate in Phase 2 of the study. The length of participation is about 2 months
An End of Treatment Visit will be conducted within 7 days of last dose of RXDX-101.
A Safety Follow-Up telephone call will be conducted approximately 30 days following the last dose of RXDX-101.
Primary endpoint will be first cycle dose limiting toxicities and maximum tolerated dose
The baseline, clinical outcome, laboratory, PK, and safety data from both segments of the study will be analyzed descriptively
Regulating Affect and Physiology in Depression
Depression is a major source of disability and distress worldwide. Some types of thinking patterns and feelings may be different in people with a history of depression. However, not enough is known about how the brain influences the way people feel, such as how people help themselves to feel better. This research is being done to better understand how people's thinking affects their feelings, and how this might be related to risk for depression.
Powered by
SC CTSI